Výsledky vyhledávání

Akademický článek

A double‐blind placebo‐controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design

Autor: Ori BenAri, Shai Efrati, Amir Hadanny, Mary Sano, Barbara B. Bendlin, HungMo Lin, Xiaoyu Liu, Inbar Sela, Ganit Almog, Abigail Livny, Israel Sandler, Simona Ben‐Haim, Roy Sagi, Derek LeRoith, Michal Schnaider Beeri, Ramit Ravona‐Springer

Publikováno v: Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)

Abstract Introduction Type 2 diabetes (T2D) is a risk factor for dementia. Ischemia due to vascular pathology is hypothesized to be an underlying mechanism for this association. Hyperbaric oxygen therapy (HBOT) is a treatment in which oxygen‐enrich

Externí odkaz: https://doaj.org/article/28502a3f95c44bd488e5881b7b1fc648

Zobrazit plný text záznamu

A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design

Autor: Mary Sano, Michal Schnaider Beeri, Derek LeRoith, Amir Hadanny, Roy Sagi, Inbar Sela, Ramit Ravona-Springer, Barbara B. Bendlin, Israel Sandler, Shai Efrati, Xiaoyu Liu, Hung-Mo Lin, Abigail Livny, Simona Ben-Haim, Ganit Almog, Ori Benari

Publikováno v: Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)

Introduction Type 2 diabetes (T2D) is a risk factor for dementia. Ischemia due to vascular pathology is hypothesized to be an underlying mechanism for this association. Hyperbaric oxygen therapy (HBOT) is a treatment in which oxygen‐enriched air (u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d553337374fd1d9c15666afe2ccd5f3b
https://pubmed.ncbi.nlm.nih.gov/32296731

Zobrazit plný text záznamu

OR14-1 Pharmacodynamics, Safety, Tolerability, and Efficacy of Oral Insulin Formulation (Oshadi Icp) among Young Adults with Type 1 Diabetes: A Summary of Clinical Studies Phases I, Ib, and Ii

Autor: Avital Leshem, Keren Doenyas-Barak, Roy Sagi, Shlomit Koren, Galia Barash, Marianna Rachmiel

Publikováno v: Journal of the Endocrine Society

Background Replacement of subcutaneous (SC) insulin by oral insulin for Type I diabetes (T1D) could promote patient compliance and minimize hyperinsulinemia. Oshadi Drug Administration Ltd. has developed an oral carrier for proteins delivery, compose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b22c0c5460607b535ddc6adefedd1c8
https://doi.org/10.1210/js.2019-or14-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání